FL-LUMOS-DIAGNOSTICS
5.2.2020 13:26:12 CET | Business Wire | Press release
Lumos Diagnostics announced the closing of U.S. $15 million in Series A funding from Planet Innovation , an Australia-based healthtech innovation and commercialization company. This funding will support the international commercial expansion of the FebriDx® rapid point-of-care (POC) test, the FebriDx U.S. FDA pivotal clinical trial, and additional development and manufacturing resources for the company’s expanding full-service POC business.
Lumos Diagnostics, a spinout from Planet Innovation, merged with RPS Diagnostics in May 2019, creating a diverse healthcare company that combines the FebriDx test and commercial experience with a novel and proprietary digital reader platform. Sam Lanyon, chairman of the board for Lumos Diagnostics and co-chief executive officer for Planet Innovation states, “Planet Innovation is focused on breakthrough technology and making investments that will have a global impact on healthcare. It is obvious that Lumos Diagnostics is poised for rapid growth and Planet Innovation is keen to support and accelerate the process.”
FebriDx is a rapid POC test that provides clinicians with an in-office assessment of the body’s immune response to acute respiratory infection (ARI). More than 50% of all unnecessary antibiotic prescriptions are for outpatient ARIs which may be associated with nonspecific flu-like symptoms, including fever, sore throat, cough, nasal congestion and fatigue. Only bacterial infections benefit from antibiotic treatment. The single-use FebriDx test identifies patients of all ages within 10 minutes who have a clinically significant underlying infection and aids in the differentiation of viral and bacterial ARIs through the simultaneous detection of both Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) directly from a fingerstick blood sample.
MxA is highly specific and elevates in the presence of acute viral infection while CRP is a nonspecific inflammatory protein that elevates in the presence of clinically significant infection. The simultaneous, combined interpretation of both MxA and CRP leads to sensitive and specific test results. With a 97-99% negative predictive value for ruling out bacterial infections, the FebriDx test may help to limit the amount of unnecessary antibiotic prescriptions that can lead to avoidable adverse reactions and antibiotic resistance, resulting in lower costs.
Robert Sambursky, MD, president and chief executive officer of Lumos Diagnostics states, “FebriDx helps advise antibiotic decisions for outpatient ARI while saving clinician time, improving workflow and reducing overall costs. The novel digital reader technology that Lumos offers as part of our complete POC service solution will be used in the next generation digital FebriDx test, providing faster time to results, identification of the rare co-infection and enhanced objectivity of test result interpretations.”
Lumos Diagnostics
Lumos Diagnostics provides rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions that utilize proprietary digital reader platforms to help healthcare professionals more accurately diagnose and manage diseases and medical conditions. Lumos provides assay development and manufacturing services for customized POC tests as well as directly develops, manufactures and will commercialize a suite of proprietary Lumos-branded POC tests that focus on the systemic host immune response. Lumos’s tests target infectious and inflammatory diseases with unmet diagnostic needs. Actionable results lead to less unnecessary treatments with associated adverse events, reduced spread of disease and more effective clinical management and therapeutic decisions.
The FebriDx test has received HealthCanada approval, Saudi Arabia FDA clearance, Singapore HSA registration, Pakistan DRAP registration and is CE marked for sale in Europe. At this time, FebriDx has not received U.S. Food and Drug Administration (FDA) clearance and is not commercially available in the United States. For more information on Lumos Diagnostics, visit www.lumosdiagnostics.com , and for more information on FebriDx, visit www.febridx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blind Sailor Mitsuhiro Iwamoto Redefines the Limits of Possibility Through Technology in a Historic Trans-Pacific Project3.2.2026 04:00:00 CET | Press release
- “HIRO’s CHOICE”: A Solo, Non-Stop Crossing of the Pacific Ocean - Mitsuhiro Iwamoto, a Japanese sailor based in San Diego, who is taking on the world’s first solo, non-stop trans-Pacific crossing by a blind sailor as part of the Blind Sailor Single-Handed Pacific Crossing Project 2027, held a press conference on January 28 (local time) in San Diego, USA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128531637/en/ Hiro Iwamoto / Global Keynote Speaker, First Totally Blind Sailor to Cross the Pacific Project URL: https://hiros-choice.com/ On January 22 (local time), Iwamoto delivered a speech at the World Economic Forum Annual Meeting 2026 (WEF) under the theme “Sailing Through Barriers.” Speaking about the upcoming voyage, he said, “Boundaries are not decided by others. They are transcended by choice.” WEF URL: https://www.weforum.org/meetings/world-economic-forum-annual-meeting-2026/sessions/sailing-through-barriers/ D
TestMu AI (Formerly LambdaTest) Recognized in Independent Research on Autonomous Testing Platforms, Q4 20252.2.2026 18:24:00 CET | Press release
Research cites AI testing, data generation, and accelerated execution TestMu AI (formerly known as LambdaTest), the world’s first full-stack Agentic Quality Engineering platform, today announced its inclusion in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025, an independent research report evaluating vendors in the autonomous testing market. The report identifies TestMu AI as a cloud-based platform for unified test orchestration and execution. It notes the platform's capabilities in cross-browser testing, real device cloud, and AI-driven automation. Specifically, the research cites TestMu AI’s testing of AI systems across dimensions, providing metrics for accuracy, intent recognition, and hallucination detection with configurable thresholds. Additionally, the report recognizes TestMu AI’s AI-powered test data generation, citing its support for Large Language Models (LLMs), multimodal inputs, and compliance-aligned workflows. The report also noted the company's strong commun
Current Chemicals Launches as Independent Specialty Materials Manufacturer, Building on 75-Year GE Legacy with Backing from Momentum Global Ventures2.2.2026 17:04:00 CET | Press release
Today marks the debut of Current Chemicals, Inc. (CCI) as a fully independent U.S.-based specialty materials manufacturer. Backed by strategic investor Momentum Global Ventures, CCI is charting a bold new path as a trusted partner for materials innovation, custom chemistry, and U.S.-based downstream manufacturing of rare earths and critical materials. The partnership between U.S.-based CCI and Netherlands-based Momentum Global Ventures reflects a strengthening transatlantic alliance at a pivotal moment for global supply chains. This partnership underscores a shared commitment to secure, reliable, and innovation-driven materials infrastructure. Originally the chemical division of GE Lighting, the team behind CCI has served as the quiet force behind groundbreaking technologies for more than 75 years, developing processes and manufacturing advanced materials for displays, lighting, energy storage, and more. As an independent company, CCI is poised to expand its impact across industries de
Laserfiche’s Taylor Grosso Honored as 2026 CRN® Channel Chief2.2.2026 16:00:00 CET | Press release
Laserfiche — the leading SaaS provider of intelligent content management — announced today that CRN® — a brand of The Channel Company — has selected Taylor Grosso, senior director, channel, Americas, as a 2026 CRN® Channel Chief. This annual recognition celebrates IT vendor and distribution executives who are shaping channel strategy and driving innovation and partnership across the industry. Grosso oversees Laserfiche’s Americas channel sales team, including the U.S., Canada, and Latin America, focusing on empowering Laserfiche Solution Providers to stay competitive as the market evolves. As more organizations seek out AI-powered tools to enhance productivity, Grosso prepares partners with the resources they need to quickly learn and sell Laserfiche’s industry-leading AI-powered document management solutions. By working closely with partners on building targeted business plans, Grosso and his team enable faster customer adoption of AI while driving revenue growth. “Over the past year,
Conga Completes Acquisition of PROS B2B Business2.2.2026 15:55:00 CET | Press release
Redefines Commercial Excellence for Enterprises with a Clear Path from Price to Signature Conga, a leader for AI-powered innovation in configure, price, quote (CPQ), contract lifecycle management (CLM), and document automation, today announced it has completed the acquisition of the B2B business of PROS Holdings, Inc (“PROS”) from certain investment funds affiliated with Thoma Bravo, the world’s largest software-focused investment firm. This transaction unites two industry leaders to help enterprises maximize revenue, reduce risk, and improve profitability. By bringing together AI-driven pricing optimization, configuration, quoting, and contracting capabilities, the combined company creates a differentiated enterprise platform that connects the commerce chain and enables end-to-end revenue orchestration from price to signature. The expanded Conga leadership team will continue to be led by CEO Dave Osborne. “To operate as connected, intelligent businesses, enterprises need a commerce ch
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom